The share prices of several pharmaceutical stocks have reached a record high, and the value of five pharmaceutical stocks has exceeded 100 billion yuan

[pharmaceutical network pharmaceutical stock market] at present, from various signs of the stock market, pharmaceutical stocks have begun to pick up Securities analysts believe that the current trend of Hong Kong stock market stock plate differentiation, medicine, consumption and other strong plates are expected to maintain strong Among them, pharmaceutical stocks in Hong Kong stocks rose generally, while those in Shiyao group, dongyangyao, Sansheng pharmaceutical, Baiyunshan, Yuanda pharmaceutical and LVYE pharmaceutical all rose by more than 3% The share prices of Hengrui pharmaceutical, Wuxi Pharmaceutical Co., Ltd., Changchun Hi Tech Co., Ltd and Aier ophthalmology Co., Ltd have reached a record high According to the top 10 list of pharmaceutical stocks published by an institution, 5 Pharmaceutical stock markets have exceeded the scale of 100 billion Hengrui pharmaceutical, a pharmaceutical company with a market value of more than 100 billion On November 3, 2017, Hengrui pharmaceutical became the first pharmaceutical stock with a market value of more than 200 billion yuan; in June 2018, the market value exceeded 300 billion yuan; on October 11, the global "stock disaster" closed with a market value of 204.6 billion yuan; one year later, Hengrui pharmaceutical again set a new high, and as of October 14, 2019, it closed with a market value of 369.6 billion yuan Compared with a year ago, the market value soared by more than 150 billion yuan Hengrui pharmaceutical has been regarded by many investors as the "big white horse" of a share and the "big brother of market value" of pharmaceutical sector Since its listing, Hengrui pharmaceutical's performance has increased steadily, while its share price has also risen all the way, up nearly 90% in the year Since its listing, Hengrui pharmaceutical's performance has increased steadily, while its share price has also risen all the way, up nearly 90% in the year In 2016, the net profit growth rate of Hengrui pharmaceutical was 18.4456%, and in 2018, it was 23.3295% The steady growth of the net profit growth rate of the enterprise proves that the profitability of Hengrui pharmaceutical is constantly strengthening Mindray medical In the first half of this year, Mindray medical realized revenue of 8.206 billion yuan, a year-on-year increase of 20.52%; net profit of 2.369 billion yuan, a year-on-year increase of 26.57%; on October 14, Mindray medical disclosed the performance forecast of the first three quarters, and the performance forecast of the third quarter in 2019, which is expected to achieve revenue of 11.822-12.550 billion yuan, a year-on-year increase of 15-25%, and net profit of 3.476-3.766 billion yuan, a year-on-year increase of 20-30%; meanwhile It is predicted that in 2019, the operating revenue will be 15.8-17.2 billion yuan, up 15-25% year on year, and the net profit attributable to the parent company will be 4.5-4.8 billion yuan, up 20-30% year on year As of October 14, the total market value reached 218.8 billion yuan Meirui medical said that the company's performance growth was mainly due to the steady and rapid growth on the basis of high income and profit scale On the one hand, with the expansion of scale at home and abroad, the company's brand influence continued to increase, and the market share of the three main core varieties steadily increased In addition, emerging businesses such as chemiluminescence continued to make rapid growth, on the other hand, the company strengthened its internal In addition, exchange rate fluctuations and continuous innovation also have a positive impact on the company's performance As a leading pharmaceutical cro enterprise, Wuxi apptec has always been concerned On October 11, 2019, the intraday price of Wuxi apptec in a share was as high as 90.38 yuan, making its share price nearly a year old As of October 14, according to the calculation of the closing price on that day, the market value of Wuxi apptec has reached 144.6 billion yuan Previously, according to the 2019 half year report issued by Wuxi apptec, its revenue in the first half of the year was 5.894 billion yuan, up 33.68% year on year; the net profit attributable to shareholders of listed companies was 1.057 billion yuan, down 16.91% year on year According to the analysis, its revenue growth benefited from the performance of major business sectors As a small molecule pharmaceutical R & D service enterprise, Wuxi apptec mainly provides "R & D outsourcing" services to domestic and foreign pharmaceutical enterprise customers The layout of Wuxi apptec mainly focuses on the whole industrial chain, running through drug discovery, pre clinical development, clinical research, and commercial production In terms of main business, Wuxi apptec can be divided into four parts: laboratory services in China, cdmo / CMO services, laboratory services in the United States, clinical research and other cro services Among them, clinical cro business increased by more than 100% As one of the 28 listed companies in the early gem, the share price of Aier ophthalmology rose 10 times in 10 years Since its listing, both the revenue and the net profit attributable to the parent company have increased rapidly In 2008-2018, the revenue and the net profit attributable to the parent company increased from 440 million yuan and 61 million yuan to 8.009 billion yuan and 1.009 billion yuan respectively, becoming the leader of professional ophthalmic medical institutions Some time ago, it published the 2019 half year report In the first half of the year, the revenue of aer ophthalmology increased by 25.64% year on year, and the net profit attributable to the mother increased by 36.53% year on year On October 15, aer eye's share price peaked at 37.43 yuan, a record high for two consecutive days By the end of the day, the closing price of Aier ophthalmology was 37.2 yuan, up 1.64%, with a daily turnover of 409 million yuan and a turnover rate of 0.44% According to the closing price, the total market value of Aier ophthalmology has reached 115.239 billion yuan Yunnan Baiyao on October 14, the volume of Yunnan Baiyao increased and stopped, with a daily turnover of 1.875 billion yuan, a new record of single day turnover this year As of October 14, the total market value reached 106.9 billion yuan Its last trading limit was on May 7, 2018 Yunnan Baiyao's share price soared this time, not only because of the multiple advantages of the overall market environment, but also because of the incentive fund of employee stock ownership plan previously launched by Yunnan Baiyao In the first half of this year, Yunnan Baiyao achieved a revenue of 13.897 billion yuan, a year-on-year increase of 5.72%; and a net profit of 2.247 billion yuan, a year-on-year increase of 8.59% According to the data, Yunnan Baiyao focuses on the four core sectors of medicine, health products, traditional Chinese medicine resources and medicine business While vigorously promoting product innovation, the company is also expanding its brand influence by combining current consumption trends and creating popular IP.